The challenges of translation
Abstract Cancer immunotherapy is a highly active area in translational medicine where the challenges and rewards of developing new drugs “from bench to bedside” become particularly visible. Here, we comment on both, the scientific and non‐scientific hurdles of this translational process using the ex...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2019-10-01
|
| Series: | EMBO Molecular Medicine |
| Online Access: | https://doi.org/10.15252/emmm.201910874 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849343132049604608 |
|---|---|
| author | Helmut R Salih Gundram Jung |
| author_facet | Helmut R Salih Gundram Jung |
| author_sort | Helmut R Salih |
| collection | DOAJ |
| description | Abstract Cancer immunotherapy is a highly active area in translational medicine where the challenges and rewards of developing new drugs “from bench to bedside” become particularly visible. Here, we comment on both, the scientific and non‐scientific hurdles of this translational process using the example of bispecific antibodies (bsAbs) and chimeric antigen receptor (CAR) T cells, two closely related strategies for antibody‐guided recruitment of T cells against cancer. Both exert impressive therapeutic activity and were recently approved for treatment of B‐cell malignancies. We discuss how the efficacy of these auspicious therapeutic tools may be further improved, in particular against solid tumors, but we also address another critical issue: Since both approaches were already introduced in the 1980s, why did it take almost thirty years until they became clinically available? |
| format | Article |
| id | doaj-art-0dde4d3e2d5b43839b4a942320891a2e |
| institution | Kabale University |
| issn | 1757-4676 1757-4684 |
| language | English |
| publishDate | 2019-10-01 |
| publisher | Springer Nature |
| record_format | Article |
| series | EMBO Molecular Medicine |
| spelling | doaj-art-0dde4d3e2d5b43839b4a942320891a2e2025-08-20T03:43:10ZengSpringer NatureEMBO Molecular Medicine1757-46761757-46842019-10-0111121310.15252/emmm.201910874The challenges of translationHelmut R Salih0Gundram Jung1Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University of TübingenDepartment of Immunology, Institute for Cell Biology, University of TübingenAbstract Cancer immunotherapy is a highly active area in translational medicine where the challenges and rewards of developing new drugs “from bench to bedside” become particularly visible. Here, we comment on both, the scientific and non‐scientific hurdles of this translational process using the example of bispecific antibodies (bsAbs) and chimeric antigen receptor (CAR) T cells, two closely related strategies for antibody‐guided recruitment of T cells against cancer. Both exert impressive therapeutic activity and were recently approved for treatment of B‐cell malignancies. We discuss how the efficacy of these auspicious therapeutic tools may be further improved, in particular against solid tumors, but we also address another critical issue: Since both approaches were already introduced in the 1980s, why did it take almost thirty years until they became clinically available?https://doi.org/10.15252/emmm.201910874 |
| spellingShingle | Helmut R Salih Gundram Jung The challenges of translation EMBO Molecular Medicine |
| title | The challenges of translation |
| title_full | The challenges of translation |
| title_fullStr | The challenges of translation |
| title_full_unstemmed | The challenges of translation |
| title_short | The challenges of translation |
| title_sort | challenges of translation |
| url | https://doi.org/10.15252/emmm.201910874 |
| work_keys_str_mv | AT helmutrsalih thechallengesoftranslation AT gundramjung thechallengesoftranslation AT helmutrsalih challengesoftranslation AT gundramjung challengesoftranslation |